176 related articles for article (PubMed ID: 28059963)
1. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
2. Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma.
Suzuki L; Nieboer D; van Lanschot JJ; Spaander MC; Looijenga LH; Biermann K
Biomark Med; 2020 Jun; 14(9):785-793. PubMed ID: 32677456
[No Abstract] [Full Text] [Related]
3. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Honing J; Pavlov KV; Mul VE; Karrenbeld A; Meijer C; Faiz Z; Smit JK; Hospers GA; Burgerhof JG; Kruyt FA; Kleibeuker JH; Plukker JT
Radiother Oncol; 2015 Oct; 117(1):152-8. PubMed ID: 26364884
[TBL] [Abstract][Full Text] [Related]
4. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
5. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
[TBL] [Abstract][Full Text] [Related]
6. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer.
Shapiro J; Biermann K; van Klaveren D; Offerhaus GJ; Ten Kate FJ; Meijer SL; van Berge Henegouwen MI; Steyerberg EW; Wijnhoven BP; Lanschot JJ
Ann Surg; 2017 Feb; 265(2):356-362. PubMed ID: 28059964
[TBL] [Abstract][Full Text] [Related]
8. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
9. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
11. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
[TBL] [Abstract][Full Text] [Related]
13. Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma.
Gabriel E; Attwood K; Shah R; Nurkin S; Hochwald S; Kukar M
J Am Coll Surg; 2017 May; 224(5):884-894.e1. PubMed ID: 28147252
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.
Bosch DJ; Wang D; Nijsten MW; Mul VE; Hospers GA; Burgerhof JG; Struys MM; Plukker JT
Am J Surg; 2016 Jul; 212(1):89-95. PubMed ID: 27036621
[TBL] [Abstract][Full Text] [Related]
17. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus.
Visser E; Edholm D; Smithers BM; Thomson IG; Burmeister BH; Walpole ET; Gotley DC; Joubert WL; Atkinson V; Mai T; Thomas JM; Barbour AP
J Surg Oncol; 2018 Jun; 117(8):1687-1696. PubMed ID: 29806960
[TBL] [Abstract][Full Text] [Related]
19. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes.
Di Corpo M; Schlottmann F; Strassle PD; Nurczyk K; Patti MG
J Laparoendosc Adv Surg Tech A; 2019 Aug; 29(8):989-994. PubMed ID: 31246532
[No Abstract] [Full Text] [Related]
20. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
